In this issue:
- We announce the continued expansion of the BIONET portfolio with co-marketing agreements with Cancer Research Technology (Ximbio) and Liverpool ChiroChem
- BIONET releases New 5-trifluoromethyl-2,3-disubstituted pyridines
- Describes how Key Organics has synthesised Risperidone-d4 and how we can help with your Isotope Labelled Compound requirements
- Features the 2nd Generation BIONET Premium Fragment Library which is now available
- DABAL-Me3 – a versatile tool for modern chemistry and now part of the BIONET collection
- Profile our event attendance at conferences and exhibitions this quarter
